文献速递乳腺乳腺X线

有乳腺癌个人史女性的二维数字乳腺摄影与数字乳腺断层合成筛查乳腺摄影性能指标比较

Screening Mammography Performance Metrics of 2D Digital Mammography Versus Digital Breast Tomosynthesis in Women With a Personal History of Breast Cancer.
PubMed 文献 · AJR Am J Roentgenol · 2020-09-23

该回顾性研究比较了有乳腺癌个人史的女性接受FFDM(5706次检查/4091例)与DBT(4440次检查/3647例)筛查的性能。DBT组召回率显著低于FFDM组(7.9% vs 10.1%,p<.001),敏感度(96.4% vs 71.4%,p=.008)和特异度(92.3% vs 90.0%,p<.001)更高,但PPV1和癌症检出率无显著差异。在非致密乳腺患者中,DBT较FFDM降低召回率并提高敏感度和特异度。

要点

  • 有乳腺癌个人史女性DBT筛查召回率7.9%,低于FFDM的10.1%(p<.001)。
  • DBT敏感度96.4%高于FFDM的71.4%(p=.008),特异度92.3%高于90.0%(p<.001)。
  • DBT与FFDM的PPV1(7.7% vs 6.1%,p=.36)和癌症检出率(6.1/1000 vs 6.0/1000,p=.97)无显著差异。

核心结论

  • 在有乳腺癌个人史且乳腺非致密的患者中,DBT较FFDM降低召回率并提高敏感度和特异度,癌症检出率和PPV1保持不变。

研究设计与样本

  • 回顾性研究,纳入2014年10月至2016年9月接受筛查FFDM的连续登记患者(5706次检查/4091例)和2017年2月至2018年12月接受筛查DBT的患者(4440次检查/3647例),均为有乳腺癌个人史且接受乳房切除术或肿块切除术治疗者。
  • 通过机构乳腺摄影数据库获取影像类型、乳腺密度、乳房切除术或肿块切除术史及BI-RADS分类,通过机构乳腺癌登记库确定癌症诊断,比较FFDM与DBT组的筛查性能指标。

诊断标准与关键数值

  • DBT召回率7.9% vs FFDM 10.1%(p<.001)。
  • DBT PPV1 7.7% vs FFDM 6.1%(p=.36);DBT癌症检出率6.1/1000 vs FFDM 6.0/1000(p=.97)。
  • DBT敏感度96.4% vs FFDM 71.4%(p=.008);DBT特异度92.3% vs FFDM 90.0%(p<.001)。
  • 非致密乳腺患者中,DBT召回率5.9% vs FFDM 8.8%(p<.001),PPV1 12.0% vs 6.4%(p=.05,差异未达统计学显著)。
  • 乳房切除术患者召回率DBT 7.8% vs FFDM 9.1%(p=.09);肿块切除术患者召回率DBT 7.9% vs FFDM 11.0%(p=.002)。

临床应用与阅片要点

  • 对有乳腺癌个人史且乳腺非致密的女性,DBT较FFDM降低召回率并提高敏感度和特异度,癌症检出率和PPV1不变。
  • DBT在保持早期癌症检出获益的同时可能减少假阳性结果的潜在危害。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Patients with a history of breast cancer are at higher risk of subsequent breast cancers and need close clinical and imaging follow-up. Limited data are available on screening of these patients with digital breast tomosynthesis (DBT) versus full-field digital mammography (FFDM). OBJECTIVE. The purpose of this study was to evaluate the screening mammography performance of DBT compared with FFDM among patients with a history of breast cancer undergoing imaging at a large academic oncology center. METHODS. This retrospective study included consecutively registered patients with a personal history of breast cancer treated with mastectomy or lumpectomy who underwent screening FFDM from October 2014 through September 2016 (5706 examinations of 4091 patients) or screening DBT from February 2017 through December 2018 (4440 examinations of 3647 patients). An institutional mammographic database was queried to obtain imaging type, breast density, history of mastectomy or lumpectomy, and BI-RADS category. An institutional breast cancer registry identified cancer diagnoses. Screening performance metrics were compared between FFDM and DBT groups. RESULTS. Recall rate was significantly lower with DBT than with FFDM (7.9% vs 10.1%; p < .001). DBT and FFDM did not differ in PPV1 (7.7% vs 6.1%; p = .36) or cancer detection rate (CDR) (6.1/1000 vs 6.0/1000; p = .97). Sensitivity was 96.4% for DBT and 71.4% for FFDM (p = .008). Specificity was 92.3% for DBT and 90.0% for FFDM (p < .001). With stratification by breast density, patients with nondense breast tissue had a lower recall rate with DBT than with FFDM (5.9% vs 8.8%; p < .001) and a nonsignificant increase in PPV1 (12.0% vs 6.4%; p = .05). The metrics were not otherwise different between DBT and FFDM among patients with nondense and those with dense breast tissue. Recall rates were lower with DBT than with FFDM among both patients who underwent mastectomy (7.8% vs 9.1%; p = .09) and those who underwent lumpectomy (7.9% vs 11.0%; p = .002). PPV1 and CDR were not different between DBT and FFDM among patients who underwent mastectomy and those who underwent lumpectomy. CONCLUSION. For patients with a personal history of breast cancer who have nondense breasts, the use of DBT as opposed to FFDM reduces recall rate and improves sensitivity and specificity. CDR and PPV1 remain unchanged. CLINICAL IMPACT. For women with a personal history of breast cancer and nondense breasts, DBT offers the potential to maintain the benefits of early cancer detection while reducing the potential harms of false-positive findings.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Chikarmane SA, Cochon LR, Khorasani R, et al. Screening Mammography Performance Metrics of 2D Digital Mammography Versus Digital Breast Tomosynthesis in Women With a Personal History of Breast Cancer. AJR Am J Roentgenol. 2020. PMID: 32966113. doi:10.2214/AJR.20.23976

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。